Radiopharm Theranostics Files 6-K

TL;DR

Radiopharm Theranostics files routine 6-K, confirms 20-F reporting.

AI Summary

Radiopharm Theranostics Limited, a foreign private issuer, filed a Form 6-K on December 15, 2025. The filing indicates the company is subject to reporting requirements under the Securities Exchange Act of 1934 and will file annual reports under Form 20-F. The company's principal executive office is located in Carlton South, Victoria, Australia.

Why It Matters

This filing is a routine disclosure for foreign private issuers, providing an update on their reporting status and administrative information to the SEC.

Risk Assessment

Risk Level: low — This is a standard administrative filing for a foreign private issuer and does not contain material new financial or operational information.

Key Players & Entities

• Radiopharm Theranostics Limited (company) — Registrant
• 001-41621 (company) — SEC File Number
• Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (company) — Principal executive office address
• Form 20-F (company) — Annual report form
• Form 6-K (company) — Filing type

FAQ

Filing Documents

• ea0269655-6k_radio.htm (6-K) — 13KB
• ea026965501ex99-1_radio.htm (EX-99.1) — 19KB
• ex99-1_001.jpg (GRAPHIC) — 10KB
• 0001213900-25-121465.txt ( ) — 47KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published an announcement (the “Public Notice”) to the Australian Securities Exchange on December 15, 2025 titled: “RAD101 interim Phase 2b data - 92% achieve primary endpoint” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 RAD101 interim Phase 2b data - 92% achieve primary endpoint 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: December 15, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR